Tomas J. Heyman - Jun 2, 2022 Form 4 Insider Report for Akero Therapeutics, Inc. (AKRO)

Role
Director
Signature
/s/ Jonathan Young, attorney-in-fact
Stock symbol
AKRO
Transactions as of
Jun 2, 2022
Transactions value $
$0
Form type
4
Date filed
6/3/2022, 04:06 PM
Previous filing
Aug 5, 2021
Next filing
Jun 9, 2022

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AKRO Stock Option (Right to Buy) Award $0 +15K $0.00 15K Jun 2, 2022 Common Stock 15K $8.13 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This option shall vest in full upon the earlier of (i) June 2, 2023 or (ii) the date of the next annual meeting, all vesting shall cease if the director resigns from the Board or otherwise ceases to service as a director.